{"id":48265,"date":"2022-09-12T18:02:02","date_gmt":"2022-09-12T16:02:02","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/kovina-therapeutics-receives-grant-from-nih-to-advance-human-papillomavirus-premalignant-infection-treatments\/"},"modified":"2022-09-12T18:02:02","modified_gmt":"2022-09-12T16:02:02","slug":"kovina-therapeutics-receives-grant-from-nih-to-advance-human-papillomavirus-premalignant-infection-treatments","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/kovina-therapeutics-receives-grant-from-nih-to-advance-human-papillomavirus-premalignant-infection-treatments\/","title":{"rendered":"Kovina Therapeutics Receives Grant from NIH to Advance Human Papillomavirus Premalignant Infection Treatments"},"content":{"rendered":"
\n

INDIANAPOLIS–(BUSINESS WIRE)–Kovina Therapeutics Inc. announced receipt of a Small Business Innovation Research (SBIR) one-year Phase I award from the National Institute of Allergy and Infectious Diseases (NIAID)\/NIH to treat Human Papillomavirus (HPV) premalignant infections. The award provides approximately $300,000 with the opportunity for advancement to Phase 2.\n<\/p>\n

<\/a><\/p>\n

\n\u201cWe are pleased to receive a second grant from NIH to support Kovina\u2019s research and development efforts. The award from NIAID supports the company\u2019s development of therapeutics to treat HPV premalignant infections which represent a global health challenge,\u201d said Kristin Sherman, CEO of Kovina Therapeutics.\n<\/p>\n

\n\u201cKovina\u2019s exciting, novel research proposal merited award after rigorous review by the NIH,\u201d said Dr. Elliot Androphy, CSO of Kovina Therapeutics. \u201cOur compounds specifically target an essential HPV protein expressed in early, premalignant, and cancerous pathologies. Inactivation of this protein results in the selective death of HPV infected cells. Our therapeutics are designed to stop HPV premalignant infections before cancer develops and to treat HPV cancers after detection.\u201d\n<\/p>\n

\nAbout Kovina Therapeutics<\/b>\n<\/p>\n

\nKovina Therapeutics is a biotechnology company developing first-in-class antiviral therapies to treat cancers and premalignant infections caused by Human Papillomavirus (HPV). Kovina has assembled a team of scientists and industry leaders with expertise in HPV and small molecule drug design to advance its pipeline of drug candidates. To learn more, visit www.Kovina.com<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nKristin Sherman
\n
CEO, Kovina Therapeutics Inc.
\n
317-224-9736
\n
Kristin.Sherman@kovina.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

INDIANAPOLIS–(BUSINESS WIRE)–Kovina Therapeutics Inc. announced receipt of a Small Business Innovation Research (SBIR) one-year Phase I award from the National Institute of Allergy and Infectious Diseases (NIAID)\/NIH to treat Human Papillomavirus (HPV) premalignant infections. The award provides approximately $300,000 with the opportunity for advancement to Phase 2. \u201cWe are pleased to receive a second grant … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-48265","6":"format-standard","7":"category-industry"},"yoast_head":"\nKovina Therapeutics Receives Grant from NIH to Advance Human Papillomavirus Premalignant Infection Treatments - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/kovina-therapeutics-receives-grant-from-nih-to-advance-human-papillomavirus-premalignant-infection-treatments\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Kovina Therapeutics Receives Grant from NIH to Advance Human Papillomavirus Premalignant Infection Treatments - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"INDIANAPOLIS–(BUSINESS WIRE)–Kovina Therapeutics Inc. announced receipt of a Small Business Innovation Research (SBIR) one-year Phase I award from the National Institute of Allergy and Infectious Diseases (NIAID)\/NIH to treat Human Papillomavirus (HPV) premalignant infections. The award provides approximately $300,000 with the opportunity for advancement to Phase 2. \u201cWe are pleased to receive a second grant ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/kovina-therapeutics-receives-grant-from-nih-to-advance-human-papillomavirus-premalignant-infection-treatments\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-12T16:02:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220912005806\/en\/1568544\/21\/Logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kovina-therapeutics-receives-grant-from-nih-to-advance-human-papillomavirus-premalignant-infection-treatments\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kovina-therapeutics-receives-grant-from-nih-to-advance-human-papillomavirus-premalignant-infection-treatments\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Kovina Therapeutics Receives Grant from NIH to Advance Human Papillomavirus Premalignant Infection Treatments\",\"datePublished\":\"2022-09-12T16:02:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kovina-therapeutics-receives-grant-from-nih-to-advance-human-papillomavirus-premalignant-infection-treatments\\\/\"},\"wordCount\":247,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kovina-therapeutics-receives-grant-from-nih-to-advance-human-papillomavirus-premalignant-infection-treatments\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220912005806\\\/en\\\/1568544\\\/21\\\/Logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kovina-therapeutics-receives-grant-from-nih-to-advance-human-papillomavirus-premalignant-infection-treatments\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kovina-therapeutics-receives-grant-from-nih-to-advance-human-papillomavirus-premalignant-infection-treatments\\\/\",\"name\":\"Kovina Therapeutics Receives Grant from NIH to Advance Human Papillomavirus Premalignant Infection Treatments - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kovina-therapeutics-receives-grant-from-nih-to-advance-human-papillomavirus-premalignant-infection-treatments\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kovina-therapeutics-receives-grant-from-nih-to-advance-human-papillomavirus-premalignant-infection-treatments\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220912005806\\\/en\\\/1568544\\\/21\\\/Logo.jpg\",\"datePublished\":\"2022-09-12T16:02:02+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kovina-therapeutics-receives-grant-from-nih-to-advance-human-papillomavirus-premalignant-infection-treatments\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kovina-therapeutics-receives-grant-from-nih-to-advance-human-papillomavirus-premalignant-infection-treatments\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kovina-therapeutics-receives-grant-from-nih-to-advance-human-papillomavirus-premalignant-infection-treatments\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220912005806\\\/en\\\/1568544\\\/21\\\/Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220912005806\\\/en\\\/1568544\\\/21\\\/Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kovina-therapeutics-receives-grant-from-nih-to-advance-human-papillomavirus-premalignant-infection-treatments\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Kovina Therapeutics Receives Grant from NIH to Advance Human Papillomavirus Premalignant Infection Treatments\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Kovina Therapeutics Receives Grant from NIH to Advance Human Papillomavirus Premalignant Infection Treatments - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/kovina-therapeutics-receives-grant-from-nih-to-advance-human-papillomavirus-premalignant-infection-treatments\/","og_locale":"en_US","og_type":"article","og_title":"Kovina Therapeutics Receives Grant from NIH to Advance Human Papillomavirus Premalignant Infection Treatments - Pharma Trend","og_description":"INDIANAPOLIS–(BUSINESS WIRE)–Kovina Therapeutics Inc. announced receipt of a Small Business Innovation Research (SBIR) one-year Phase I award from the National Institute of Allergy and Infectious Diseases (NIAID)\/NIH to treat Human Papillomavirus (HPV) premalignant infections. The award provides approximately $300,000 with the opportunity for advancement to Phase 2. \u201cWe are pleased to receive a second grant ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/kovina-therapeutics-receives-grant-from-nih-to-advance-human-papillomavirus-premalignant-infection-treatments\/","og_site_name":"Pharma Trend","article_published_time":"2022-09-12T16:02:02+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220912005806\/en\/1568544\/21\/Logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/kovina-therapeutics-receives-grant-from-nih-to-advance-human-papillomavirus-premalignant-infection-treatments\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/kovina-therapeutics-receives-grant-from-nih-to-advance-human-papillomavirus-premalignant-infection-treatments\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Kovina Therapeutics Receives Grant from NIH to Advance Human Papillomavirus Premalignant Infection Treatments","datePublished":"2022-09-12T16:02:02+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/kovina-therapeutics-receives-grant-from-nih-to-advance-human-papillomavirus-premalignant-infection-treatments\/"},"wordCount":247,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/kovina-therapeutics-receives-grant-from-nih-to-advance-human-papillomavirus-premalignant-infection-treatments\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220912005806\/en\/1568544\/21\/Logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/kovina-therapeutics-receives-grant-from-nih-to-advance-human-papillomavirus-premalignant-infection-treatments\/","url":"https:\/\/pharma-trend.com\/en\/kovina-therapeutics-receives-grant-from-nih-to-advance-human-papillomavirus-premalignant-infection-treatments\/","name":"Kovina Therapeutics Receives Grant from NIH to Advance Human Papillomavirus Premalignant Infection Treatments - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/kovina-therapeutics-receives-grant-from-nih-to-advance-human-papillomavirus-premalignant-infection-treatments\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/kovina-therapeutics-receives-grant-from-nih-to-advance-human-papillomavirus-premalignant-infection-treatments\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220912005806\/en\/1568544\/21\/Logo.jpg","datePublished":"2022-09-12T16:02:02+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/kovina-therapeutics-receives-grant-from-nih-to-advance-human-papillomavirus-premalignant-infection-treatments\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/kovina-therapeutics-receives-grant-from-nih-to-advance-human-papillomavirus-premalignant-infection-treatments\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/kovina-therapeutics-receives-grant-from-nih-to-advance-human-papillomavirus-premalignant-infection-treatments\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220912005806\/en\/1568544\/21\/Logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220912005806\/en\/1568544\/21\/Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/kovina-therapeutics-receives-grant-from-nih-to-advance-human-papillomavirus-premalignant-infection-treatments\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Kovina Therapeutics Receives Grant from NIH to Advance Human Papillomavirus Premalignant Infection Treatments"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/48265","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=48265"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/48265\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=48265"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=48265"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=48265"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}